Caris Life Sciences provides molecular profiling and diagnostic services for cancer treatment.
Caris reads the full exome rather than a select panel, enabling re-mining of proprietary data as new cancer biomarkers are discovered, and is already producing cash flow, potentially giving it a long-term data depth advantage over panel-based competitors.